Tomas Reischig

Summary

Affiliation: Charles University
Country: Czech Republic

Publications

  1. pmc Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation
    Tomas Reischig
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Alej Svobody 80, 304 60 Pilsen, Czech Republic
    J Am Soc Nephrol 23:1588-97. 2012
  2. doi request reprint Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients
    Tomá Reischig
    Department of Internal Medicine I, Charles University in Prague, Faculty of Medicine in Pilsen, Teaching Hospital Pilsen, Pilsen, Czech Republic
    Antivir Ther 16:1227-35. 2011
  3. doi request reprint Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy
    Tomas Reischig
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Alej Svobody 80, 304 60 Pilsen, Czech Republic
    Expert Rev Anti Infect Ther 10:51-61. 2012
  4. ncbi request reprint Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies
    Tomas Reischig
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Alej Svobody 80, 301 60 Pilsen, Czech Republic
    Expert Rev Anti Infect Ther 8:903-10. 2010
  5. doi request reprint Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients
    Tomas Reischig
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic
    Antivir Ther 15:23-30. 2010
  6. doi request reprint Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis
    Tomas Reischig
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic
    Transplantation 87:436-44. 2009
  7. ncbi request reprint Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation
    T Reischig
    Department of Internal Medicine I, Charles Medical School and Teaching Hospital, Pilsen, Czech Republic
    Am J Transplant 8:69-77. 2008
  8. ncbi request reprint The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection
    Tomas Reischig
    Department of Internal Medicine I, Charles University School of Medicine and Teaching Hospital, Alej Svobody 80, 301 60 Pilsen, Czech Republic
    J Clin Virol 36:146-51. 2006
  9. ncbi request reprint A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation
    Tomas Reischig
    Department of Internal Medicine I, Charles University Teaching Hospital, Alej Svobody 80, 30460 Pilsen, Czech Republic
    Transpl Int 15:615-22. 2002
  10. ncbi request reprint Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients
    Tomas Reischig
    Department of Internal Medicine I, Charles University School of Medicine and University Hospital, Pilsen, Czech Republic
    Kidney Blood Press Res 28:218-25. 2005

Collaborators

Detail Information

Publications22

  1. pmc Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation
    Tomas Reischig
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Alej Svobody 80, 304 60 Pilsen, Czech Republic
    J Am Soc Nephrol 23:1588-97. 2012
    ..In conclusion, compared with valacyclovir prophylaxis, pre-emptive valganciclovir therapy may lead to less severe interstitial fibrosis and tubular atrophy and to significantly better graft survival...
  2. doi request reprint Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients
    Tomá Reischig
    Department of Internal Medicine I, Charles University in Prague, Faculty of Medicine in Pilsen, Teaching Hospital Pilsen, Pilsen, Czech Republic
    Antivir Ther 16:1227-35. 2011
    ..This phenomenon might not be fully explained by preventing the indirect effects of cytomegalovirus. The effect of antiviral agents on lymphocyte function in patients treated with modern immunosuppression has not been studied to date...
  3. doi request reprint Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy
    Tomas Reischig
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Alej Svobody 80, 304 60 Pilsen, Czech Republic
    Expert Rev Anti Infect Ther 10:51-61. 2012
    ..Despite an apparent trend to prefer prophylaxis in clinical practice, this approach does not seem to be based on robust evidence...
  4. ncbi request reprint Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies
    Tomas Reischig
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Alej Svobody 80, 301 60 Pilsen, Czech Republic
    Expert Rev Anti Infect Ther 8:903-10. 2010
    ..The article will also address the potential of anti-CMV preventive protocols designed to favorably affect the incidence of allograft rejection...
  5. doi request reprint Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients
    Tomas Reischig
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic
    Antivir Ther 15:23-30. 2010
    ..Persistence of the virus within the allograft could stimulate the alloimmune response. The aim of our study was to evaluate intragraft CMV infection in patients randomized to the trial...
  6. doi request reprint Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis
    Tomas Reischig
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic
    Transplantation 87:436-44. 2009
    ..The aim of this study was to determine the impact of CMV viremia on subclinical rejection (SCR) and interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsy at 3 months after transplantation...
  7. ncbi request reprint Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation
    T Reischig
    Department of Internal Medicine I, Charles Medical School and Teaching Hospital, Pilsen, Czech Republic
    Am J Transplant 8:69-77. 2008
    ..In conclusion, preemptive valganciclovir therapy and valacyclovir prophylaxis are equally effective in the prevention of CMV disease after renal transplantation...
  8. ncbi request reprint The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection
    Tomas Reischig
    Department of Internal Medicine I, Charles University School of Medicine and Teaching Hospital, Alej Svobody 80, 301 60 Pilsen, Czech Republic
    J Clin Virol 36:146-51. 2006
    ..Cytomegalovirus (CMV) disease is a risk factor for allograft rejection in renal transplant (RTx) recipients. However, the role of asymptomatic CMV infection remains controversial...
  9. ncbi request reprint A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation
    Tomas Reischig
    Department of Internal Medicine I, Charles University Teaching Hospital, Alej Svobody 80, 30460 Pilsen, Czech Republic
    Transpl Int 15:615-22. 2002
    ..Both are cost-effective and help reduce CMV-associated costs by some 40% compared with patients without prophylaxis...
  10. ncbi request reprint Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients
    Tomas Reischig
    Department of Internal Medicine I, Charles University School of Medicine and University Hospital, Pilsen, Czech Republic
    Kidney Blood Press Res 28:218-25. 2005
    ..To compare the efficacy, costs and safety of oral ganciclovir and valacyclovir in the prophylaxis of cytomegalovirus (CMV) disease in renal transplant (RTx) recipients at high risk of CMV disease...
  11. ncbi request reprint Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection
    Tomas Reischig
    Department of Internal Medicine I, Charles University Hospital, Pilsen, Czech Republic
    Transplantation 79:317-24. 2005
    ..Moreover, valacyclovir has been shown to reduce the risk of acute rejection. Our study was designed to compare the efficacy and safety of oral ganciclovir and valacyclovir in the prophylaxis of CMV disease after renal transplantation...
  12. doi request reprint Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients
    Lukás Kielberger
    Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Plzen, Czech Republic
    Kidney Blood Press Res 35:407-16. 2012
    ..The aim of this study was to determine the cost impact of four different strategies for prevention of cytomegalovirus (CMV) disease after renal transplantation...
  13. ncbi request reprint First kidney transplantation from a non-heart-beating donor in the Czech Republic
    Vladislav Treska
    Transplant Centre, University Hospital of Plzen, Czech Republic
    Ann Transplant 7:45-9. 2002
    ..The postoperative course was uneventful and both patients could be discharged on the twenty-first day of hospitalisation for further care at home...
  14. ncbi request reprint Plasma and tissue levels of free oxygen radicals in recipients of kidneys from non-heart-beating donors: does recipient pretreatment with antioxidant drugs make sense? An experimental study in pigs
    V Treska
    Transplantion Center, Department of Surgery, University Hospital, Plzen, Czech Republic
    Transplant Proc 34:3060-4. 2002
  15. ncbi request reprint [Initial experience with transplantation of a kidney from a non-beating heart donor (NHBD)]
    V Treska
    Chirurgicka klinika FN, Plzen
    Rozhl Chir 81:582-6. 2002
    ..The initial results of renal transplantation from NHBD are promising and the programme will be developed further...
  16. ncbi request reprint Urological complications of congenital nephrogenic diabetes insipidus--long-term follow-up of one patient
    M Hora
    Department of Urology, Charles University Hospital, E Benese 13, 305 99, Plzen, Czech Republic
    Int Urol Nephrol 38:531-2. 2006
    ..Intermittent catheterization is necessary due to residual urine in the urinary bladder...
  17. ncbi request reprint Ischemia-reperfusion injury in kidney transplantation from non-heart-beating donor--do antioxidants or antiinflammatory drugs play any role?
    V Treska
    Department of Surgery, University Hospital, Plzen, Czech Republic
    Bratisl Lek Listy 110:133-6. 2009
    ..The aim of this study was to demonstrate the reduction of IRI by intravenous application of antioxidants or immunosuppressives to the recipient before the kidney transplantation in an experimental model...
  18. ncbi request reprint [Ischemia-reperfusion injury in kidney transplantation from non-heart beating donor--do antioxidants or antiinflammatory drugs play any role?]
    V Treska
    Chirurgická klinika FN a LF UK v Plzni
    Rozhl Chir 88:65-8. 2009
    ..The aim of the experimental study was to demonstrate on an experimental model the possibilities of reduction of IRI by intravenous application of antioxidants or immunosuppressives to the recipient before the kidney transplantation...
  19. doi request reprint Tumours in end-stage kidney
    M Hora
    Department of Urology, Charles University Hospital, Plzen, Czech Republic
    Transplant Proc 40:3354-8. 2008
    ..The malignant potential is unclear. The question is whether to remove both kidneys in patients with a tumor on one side only diagnosed by computed tomography (CT)...
  20. doi request reprint TSC2/PKD1 contiguous gene syndrome: a report of 2 cases with emphasis on dermatopathologic findings
    Denisa Kacerovska
    Sikl s Department of Pathology, Charles University, Medical Faculty Hospital, Pilsen, Czech Republic
    Am J Dermatopathol 31:532-41. 2009
    ....
  21. doi request reprint Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect
    Pavlina Richtrova
    Department of Internal Medicine I, Charles University, Medical School and Teaching Hospital, Plzen, Czech Republic
    Artif Organs 35:83-8. 2011
    ..The activation was significantly lower during RCA, and according to thrombogenicity, RCA is the most effective among compared anticoagulation methods...
  22. ncbi request reprint Computed tomography of renal cell carcinoma in patients with terminal renal impairment
    Jiri Ferda
    Department of Radiology, Charles University Hospital Plzen, Alej Svobody 80, CZ 306 40 Plzen, Czech Republic
    Eur J Radiol 63:295-301. 2007
    ..This study discusses the role of computed tomography (CT) in detecting renal tumors in patients with renal impairment: pre-dialysis, those receiving dialysis or with renal allograft transplants...